Shares of Moderna Inc. MRNA slipped 3.43% to $65.69 Friday, on what proved to be an all-around mixed trading session for the ...

Moderna, the Massachusetts-based biotech company that rocketed into the global spotlight during the development of its COVID-19 vaccine, announced plans on Thursday to cut costs and refocus on ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even. The company also ...

Moderna’s shares climbed in the first half of the year, as it scored victories with a product approval and solid clinical trial results. This week the biotech surprised investors with some ...

UCG / Contributor / Getty Images Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 vaccine. Moderna's Spikevax KP.2 targets the KP.2 variant of ...

[Photo: MM/Adobe Stock] BY Jennifer Mattson 1 minute read Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development (R&D) budget by about 20% over the ...

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $75.00. The ...

Moderna said Thursday it would cut its annual spending on research and development by 23%, or $1.1 billion, between 2024 and 2027 in a concession to investors who have viewed the company’s ...

SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians ...

Shares of Moderna Inc. MRNA slipped 2.63% to $68.02 Thursday, on what proved to be an all-around favorable trading session ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even. The company also ...